Acadia Pharmaceutica (ACAD) 31.59 $ACAD After Y
Post# of 273258
Posted On: 09/03/2016 1:09:08 AM
Acadia Pharmaceutica (ACAD) 31.59 $ACAD
After Yesterday's Decline of 1.03%, Acadia Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 01, 2:39PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $31.53 to a high of $32.69. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $31.85 on volume of 750,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 31.59 (-0.51)
ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer
BusinessWire - Wed Aug 24, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders, today announced the appointment of Todd S. Young as Executive Vice President, Chief Financial Officer, effective August 22, 2016. Mr. Young reports to Steve Davis, ACADIA's President and Chief Executive Officer.
ACAD: 31.59 (-0.51)
ACADIA Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
BusinessWire - Tue Aug 23, 3:40PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that the underwriters for the Company's previously announced public offering have fully exercised their option to purchase an additional 909,090 shares. All 6,969,696 shares sold in the offering were offered by ACADIA at a price to the public of $33.00 per share, for total gross proceeds to ACADIA of approximately $230.0 million before deducting underwriting discounts and commissions and other offering expenses payable by ACADIA. The closing of the sale of 6,060,606 shares was completed on August 15, 2016, and the closing of the sale of 909,090 shares pursuant to the full exercise by the underwriters of their option to purchase additional shares was completed earlier today.
ACAD: 31.59 (-0.51), JPM: 67.49 (+0.28)
Watch for Acadia Pharmaceuticals to Potentially Pullback After Gaining 1.26% Yesterday
Comtex SmarTrend(R) - Mon Aug 22, 2:22PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $33.98 to a high of $34.85. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $33.90 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 31.59 (-0.51)
Covered Call reports for Micron, Macy's Incorporated, International Business Machines, ACADIA Pharmaceuticals and Suncor Energy include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Aug 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACAD, IBM, M, MU, and SU.
SU: 27.43 (+0.50), MU: 16.70 (+0.06), ACAD: 31.59 (-0.51), IBM: 159.55 (+0.01), M: 36.64 (+0.30)
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
BusinessWire - Tue Aug 09, 7:50PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the pricing of an underwritten public offering of 6,060,606 shares of its common stock, offered at a price to the public of $33.00 per share. The gross proceeds from this offering to ACADIA are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day option to purchase up to an aggregate of 909,090 additional shares of common stock. The offering is expected to close on August 15, 2016, subject to customary closing conditions.
ACAD: 31.59 (-0.51), JPM: 67.49 (+0.28)
Look for Shares of Acadia Pharmaceuticals to Potentially Rebound after Yesterday's 3.21% Sell Off
Comtex SmarTrend(R) - Tue Aug 09, 1:12PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $32.50 to a high of $34.45. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $34.56 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 31.59 (-0.51)
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
BusinessWire - Mon Aug 08, 3:01PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it intends to offer and sell, subject to market and other conditions, $200,000,000 of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ACAD: 31.59 (-0.51), JPM: 67.49 (+0.28)
ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results
BusinessWire - Thu Aug 04, 3:05PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its unaudited financial results for the second quarter ended June 30, 2016.
ACAD: 31.59 (-0.51)
5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:36AM CDT
How will drug stocks like BMRN, TEVA, REGN and others, scheduled to report on Aug 4, fare this earnings season?
ACAD: 31.59 (-0.51), BMRN: 95.73 (+0.54), ALNY: 69.17 (+0.15), TEVA: 51.22 (+0.32), REGN: 388.64 (-4.76)
InvestorsObserver releases covered-call reports for OPKO Health, ACADIA Pharmaceuticals, Whiting Petroleum, VMware and Jabil Circuit
PR Newswire - Tue Aug 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACAD, JBL, OPK, VMW, and WLL.
WLL: 7.40 (+0.29), ACAD: 31.59 (-0.51), VMW: 73.78 (unch), OPK: 9.33 (+0.04), JBL: 21.42 (+0.13)
ACADIA (ACAD) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:54AM CDT
Investor focus will remain on the performance of ACADIA's (ACAD) recently launched Nuplazid.
ACAD: 31.59 (-0.51), RPTP: 7.28 (+0.04), TECH: 106.88 (+0.35), XLRN: 30.84 (+0.59)
ACADIA Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016
BusinessWire - Fri Jul 29, 5:15PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2016 on Thursday, August 4, 2016, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Thursday, August 4, 2016, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and operations.
ACAD: 31.59 (-0.51)
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016
BusinessWire - Thu Jun 16, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, at 9:00 a.m. Eastern Time in New York City.
ACAD: 31.59 (-0.51)
20.3% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Thu Jun 09, 1:42PM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on May 20th, 2016 at $33.51. In approximately 3 weeks, Acadia Pharmaceuticals has returned 20.27% as of today's recent price of $40.30.
ACAD: 31.59 (-0.51)
Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 80.85 (-0.08), ACAD: 31.59 (-0.51), OPK: 9.33 (+0.04), CLDX: 3.35 (-0.01)
Watch for Acadia Pharmaceuticals to Potentially Pullback After Gaining 8.48% Yesterday
Comtex SmarTrend(R) - Mon Jun 06, 2:01PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $36.48 to a high of $39.31. Yesterday, the shares gained 8.5%, which took the trading range above the 3-day high of $36.88 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 31.59 (-0.51)
Acadia Pharmaceuticals Rises 2.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 1:21PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $35.40 to a high of $36.88. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $36.40 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 31.59 (-0.51)
ACADIA Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016
BusinessWire - Wed Jun 01, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016, at 3:20 p.m. Pacific Time in Rancho Palos Verdes, California.
ACAD: 31.59 (-0.51)
ACADIA Pharmaceuticals Announces NUPLAZID(TM) (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson's Disease Psychosis
BusinessWire - Tue May 31, 7:00AM CDT
--An Estimated 40 Percent of Parkinson's Disease Patients Have Psychosis
ACAD: 31.59 (-0.51)
After Yesterday's Decline of 1.03%, Acadia Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 01, 2:39PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $31.53 to a high of $32.69. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $31.85 on volume of 750,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 31.59 (-0.51)
ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer
BusinessWire - Wed Aug 24, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders, today announced the appointment of Todd S. Young as Executive Vice President, Chief Financial Officer, effective August 22, 2016. Mr. Young reports to Steve Davis, ACADIA's President and Chief Executive Officer.
ACAD: 31.59 (-0.51)
ACADIA Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
BusinessWire - Tue Aug 23, 3:40PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that the underwriters for the Company's previously announced public offering have fully exercised their option to purchase an additional 909,090 shares. All 6,969,696 shares sold in the offering were offered by ACADIA at a price to the public of $33.00 per share, for total gross proceeds to ACADIA of approximately $230.0 million before deducting underwriting discounts and commissions and other offering expenses payable by ACADIA. The closing of the sale of 6,060,606 shares was completed on August 15, 2016, and the closing of the sale of 909,090 shares pursuant to the full exercise by the underwriters of their option to purchase additional shares was completed earlier today.
ACAD: 31.59 (-0.51), JPM: 67.49 (+0.28)
Watch for Acadia Pharmaceuticals to Potentially Pullback After Gaining 1.26% Yesterday
Comtex SmarTrend(R) - Mon Aug 22, 2:22PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $33.98 to a high of $34.85. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $33.90 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 31.59 (-0.51)
Covered Call reports for Micron, Macy's Incorporated, International Business Machines, ACADIA Pharmaceuticals and Suncor Energy include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Aug 12, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACAD, IBM, M, MU, and SU.
SU: 27.43 (+0.50), MU: 16.70 (+0.06), ACAD: 31.59 (-0.51), IBM: 159.55 (+0.01), M: 36.64 (+0.30)
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
BusinessWire - Tue Aug 09, 7:50PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the pricing of an underwritten public offering of 6,060,606 shares of its common stock, offered at a price to the public of $33.00 per share. The gross proceeds from this offering to ACADIA are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day option to purchase up to an aggregate of 909,090 additional shares of common stock. The offering is expected to close on August 15, 2016, subject to customary closing conditions.
ACAD: 31.59 (-0.51), JPM: 67.49 (+0.28)
Look for Shares of Acadia Pharmaceuticals to Potentially Rebound after Yesterday's 3.21% Sell Off
Comtex SmarTrend(R) - Tue Aug 09, 1:12PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $32.50 to a high of $34.45. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $34.56 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 31.59 (-0.51)
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
BusinessWire - Mon Aug 08, 3:01PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it intends to offer and sell, subject to market and other conditions, $200,000,000 of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ACAD: 31.59 (-0.51), JPM: 67.49 (+0.28)
ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results
BusinessWire - Thu Aug 04, 3:05PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its unaudited financial results for the second quarter ended June 30, 2016.
ACAD: 31.59 (-0.51)
5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:36AM CDT
How will drug stocks like BMRN, TEVA, REGN and others, scheduled to report on Aug 4, fare this earnings season?
ACAD: 31.59 (-0.51), BMRN: 95.73 (+0.54), ALNY: 69.17 (+0.15), TEVA: 51.22 (+0.32), REGN: 388.64 (-4.76)
InvestorsObserver releases covered-call reports for OPKO Health, ACADIA Pharmaceuticals, Whiting Petroleum, VMware and Jabil Circuit
PR Newswire - Tue Aug 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACAD, JBL, OPK, VMW, and WLL.
WLL: 7.40 (+0.29), ACAD: 31.59 (-0.51), VMW: 73.78 (unch), OPK: 9.33 (+0.04), JBL: 21.42 (+0.13)
ACADIA (ACAD) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:54AM CDT
Investor focus will remain on the performance of ACADIA's (ACAD) recently launched Nuplazid.
ACAD: 31.59 (-0.51), RPTP: 7.28 (+0.04), TECH: 106.88 (+0.35), XLRN: 30.84 (+0.59)
ACADIA Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016
BusinessWire - Fri Jul 29, 5:15PM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2016 on Thursday, August 4, 2016, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Thursday, August 4, 2016, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and operations.
ACAD: 31.59 (-0.51)
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016
BusinessWire - Thu Jun 16, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, at 9:00 a.m. Eastern Time in New York City.
ACAD: 31.59 (-0.51)
20.3% Return Seen to Date on SmarTrend Acadia Pharmaceuticals Call (ACAD)
Comtex SmarTrend(R) - Thu Jun 09, 1:42PM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on May 20th, 2016 at $33.51. In approximately 3 weeks, Acadia Pharmaceuticals has returned 20.27% as of today's recent price of $40.30.
ACAD: 31.59 (-0.51)
Biotechnology Stocks in Motion -- Celldex Therapeutics, Medivation, Opko Health, and ACADIA Pharma
PR Newswire - Tue Jun 07, 7:05AM CDT
On Monday, June 06, 2016, the NASDAQ Composite ended the trading session at 4,968.71, up 0.53%; the Dow Jones Industrial Average advanced 0.64% to finish at 17,920.33; and the S&P 500 closed at 2,109.41, up 0.49%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Medivation Inc. (NASDAQ: MDVN), Opko Health Inc. (NYSE: OPK), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Learn more about these stocks by accessing their free trade alerts at:
MDVN: 80.85 (-0.08), ACAD: 31.59 (-0.51), OPK: 9.33 (+0.04), CLDX: 3.35 (-0.01)
Watch for Acadia Pharmaceuticals to Potentially Pullback After Gaining 8.48% Yesterday
Comtex SmarTrend(R) - Mon Jun 06, 2:01PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $36.48 to a high of $39.31. Yesterday, the shares gained 8.5%, which took the trading range above the 3-day high of $36.88 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 31.59 (-0.51)
Acadia Pharmaceuticals Rises 2.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 1:21PM CDT
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $35.40 to a high of $36.88. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $36.40 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ACAD: 31.59 (-0.51)
ACADIA Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016
BusinessWire - Wed Jun 01, 8:00AM CDT
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016, at 3:20 p.m. Pacific Time in Rancho Palos Verdes, California.
ACAD: 31.59 (-0.51)
ACADIA Pharmaceuticals Announces NUPLAZID(TM) (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson's Disease Psychosis
BusinessWire - Tue May 31, 7:00AM CDT
--An Estimated 40 Percent of Parkinson's Disease Patients Have Psychosis
ACAD: 31.59 (-0.51)
(0)
(0)Scroll down for more posts ▼